← Back to Screener
Halozyme Therapeutics, Inc. (HALO)
Price$66.64
Favorite Metrics
Price vs S&P 500 (26W)0.39%
Price vs S&P 500 (4W)1.09%
Market Capitalization$8.01B
P/E Ratio (Annual)25.28x
All Metrics
P/CF (Annual)12.30x
Book Value / Share (Quarterly)$0.41
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)28.38%
Cash Flow / Share (Quarterly)$3.03
Price vs S&P 500 (YTD)-1.53%
Gross Margin (TTM)83.62%
Net Profit Margin (TTM)22.69%
EPS (TTM)$2.49
10-Day Avg Trading Volume1.36M
EPS Excl Extra (TTM)$2.49
Revenue Growth (5Y)39.16%
EPS (Annual)$2.56
ROI (Annual)14.46%
Gross Margin (Annual)83.62%
Net Profit Margin (5Y Avg)44.37%
Cash / Share (Quarterly)$1.21
P/E Basic Excl Extra (TTM)25.28x
Revenue Growth QoQ (YoY)51.60%
EPS Growth (5Y)22.89%
P/E Normalized (Annual)25.28x
ROA (Last FY)12.55%
Revenue Growth TTM (YoY)37.55%
EBITD / Share (TTM)$4.40
ROE (5Y Avg)286.14%
Operating Margin (TTM)33.19%
Cash Flow / Share (Annual)$3.03
P/B Ratio164.13x
P/B Ratio (Quarterly)162.13x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)7.17x
Net Interest Coverage (TTM)143.47x
ROA (TTM)14.09%
EV / EBITDA (TTM)18.55x
EPS Incl Extra (Annual)$2.56
Current Ratio (Annual)4.66x
Quick Ratio (Quarterly)3.30x
3-Month Avg Trading Volume1.87M
52-Week Price Return10.85%
EV / Free Cash Flow (Annual)28.08x
P/E Incl Extra (TTM)25.28x
Revenue / Employee (TTM)$3
Tangible BV / Share (Quarterly)$1.32
P/S Ratio (Annual)5.74x
Asset Turnover (Annual)0.55x
52-Week High$82.22
Operating Margin (5Y Avg)45.17%
EPS Excl Extra (Annual)$2.56
CapEx CAGR (5Y)159.60%
26-Week Price Return4.37%
Quick Ratio (Annual)3.30x
13-Week Price Return-6.03%
Total Debt / Equity (Annual)43.89x
Current Ratio (Quarterly)4.66x
Enterprise Value$10,020.634
Revenue / Share Growth (5Y)42.91%
Asset Turnover (TTM)0.62x
Book Value / Share Growth (5Y)-18.01%
Revenue / Employee (Annual)$3
Inventory Turnover (Annual)1.44x
Pretax Margin (Annual)33.43%
Cash / Share (Annual)$1.21
3-Month Return Std Dev34.37%
Gross Margin (5Y Avg)81.05%
Net Income / Employee (TTM)$1
EBITDA CAGR (5Y)29.63%
ROE (Last FY)649.18%
Net Interest Coverage (Annual)-39.65x
EPS Basic Excl Extra (Annual)$2.56
P/FCF (TTM)13.30x
Receivables Turnover (TTM)3.73x
EV / Free Cash Flow (TTM)28.08x
Total Debt / Equity (Quarterly)43.89x
EPS Incl Extra (TTM)$2.49
Receivables Turnover (Annual)3.73x
ROI (TTM)15.77%
P/S Ratio (TTM)5.74x
Pretax Margin (5Y Avg)44.82%
Revenue / Share (Annual)$11.27
Tangible BV / Share (Annual)$-5.81
Forward P/E8.54x
Free OCF CAGR (5Y)46.43%
Price vs S&P 500 (52W)-18.98%
P/E Ratio (TTM)25.28x
EPS Growth TTM (YoY)-27.39%
Year-to-Date Return1.11%
5-Day Price Return1.45%
EPS Normalized (Annual)$2.56
ROA (5Y Avg)19.55%
Net Profit Margin (Annual)22.69%
Month-to-Date Return5.29%
Cash Flow / Share (TTM)$2.37
EBITD / Share (Annual)$4.36
EPS Growth (3Y)21.17%
Operating Margin (Annual)33.19%
LT Debt / Equity (Annual)43.89x
P/CF (TTM)12.30x
ROI (5Y Avg)21.11%
P/E Excl Extra (TTM)25.28x
LT Debt / Equity (Quarterly)43.89x
EPS Basic Excl Extra (TTM)$2.49
P/TBV (Quarterly)55.21x
P/B Ratio (Annual)162.13x
Inventory Turnover (TTM)1.44x
Pretax Margin (TTM)33.43%
Book Value / Share (Annual)$0.41
Price vs S&P 500 (13W)-6.72%
Net Margin Growth (5Y)-14.00%
Beta0.97x
P/FCF (Annual)22.45x
Revenue / Share (TTM)$11.87
ROE (TTM)92.67%
52-Week Low$47.50
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.80
3.80
3.80
3.80
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
KRYSKrystal Biotech, Inc. Common Stock | 20.17x | 33.95% | 94.08% | — | $264.06 |
About
Halozyme Therapeutics develops oncology therapies that target human enzymes to alter tumor progression. The company advances its pipeline through both internal development and partnerships with biopharmaceutical companies to commercialize its proprietary technology. Operations are primarily US-based with minimal international assets.